Immunomedics (IMMU) Reports Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer
Go back to Immunomedics (IMMU) Reports Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer| Immunomedics, Inc. (NASDAQ: IMMU) | Delayed: 87.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $87.86 | 52 Week High | $5.44 | |||
| Open | $238.99 | 52 Week Low | $1.61 | |||
| Day High | $87.86 | P/E | N/A | |||
| Day Low | $87.86 | EPS | $-0.15 | |||
| Volume | 300,340 | |||||
